ABSTRACT A 2-year, placebo-controlled, double-blind, crossover study was started in 1992 to evaluate cladribine, an immunosuppressive drug, in the treatment of chronic progressive multiple sclerosis. In the first year patients were given cladribine 0.10 mg/kg per day for 7 days as four monthly courses for a total of 2.8 mg/kg or placebo. During the second year patients treated with placebo during the first year were given i.v. infusions of 0.10 mg, 0.05 mg, and 0. Since there is no satisfactory treatment for chronic progressive MS, the use of cladribine was considered because of its relatively low toxicity and the long-lasting lymphopenia that it produces. Open-label feasibility studies were begun in 1990 with a small number of patients. The results in terms of both apparent benefit on neurological performance and lack of toxicity were favorable and encouraged us to proceed with a larger 2-yr placebo-controlled crossover study to further explore issues of safety and therapeutic effect. The first-year results of this study showed a positive effect (7). We now report observations from the entire 2 yr of this double-blind study and an additional 6-mo unblinded follow-up. tTo whom reprint requests should be addressed at:
Although the underlying cause of multiple sclerosis (MS) remains a mystery, considerable evidence exists that damage to the central nervous system is mediated by immunopathologic mechanisms (1, 2) . For this reason, immunosuppression is a rational approach to treatment of this disorder.
2-Chlorodeoxyadenosine (2-CdA; cladribine; Leustatin) is an adenosine deaminase-resistant purine nucleoside, designed by Carson et al. (3) (4) (5) to simulate the immunodeficiency state of hereditary adenosine deaminase deficiency by causing the accumulation of deoxynucleotides in lymphocytes. This simple compound has been widely used for the treatment of lymphoid malignancies (6) and has a very favorable toxicity profile relative to other lymnphocytolytic drugs.
Since there is no satisfactory treatment for chronic progressive MS, the use of cladribine was considered because of its relatively low toxicity and the long-lasting lymphopenia that it produces. Open-label feasibility studies were begun in 1990 with a small number of patients. The results in terms of both apparent benefit on neurological performance and lack of toxicity were favorable and encouraged us to proceed with a larger 2-yr placebo-controlled crossover study to further explore issues of safety and therapeutic effect. The first-year results of this study showed a positive effect (7) . We now report observations from the entire 2 yr of this double-blind study and an additional 6-mo unblinded follow-up.
METHODS
Patient Selection. The study subjects were 51 patients with clinically definite or laboratory-supported definite chronic
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progressive MS (8) Proc. Natl. Acad. Sci. USA 93 (1996) (9) and with the SNRS (10) . MRI brain scans with contrast enhancement were performed in these patients before treatment and at 6-mo intervals.
To assess inter-rater variability 20 patients were independently assessed by each examiner (J.S.R., J.C.S.) on the same day. Interrater agreement (11) (14) . Last available observations were carried forward for patients who had completed at least 18 mo of the study. Similar analyses were done in which these data remained missing and in which they were modeled under the representation that they were missing at random; these analyses yielded similar results to those reported here. KaplanMeier curves and log-rank statistics were also used to compare neurological rating-scale outcomes between the two treatment groups during the first year of the study. Two-sided P values are reported throughout.
RESULTS
Neurologic Findings. Clinical performance scores. Fig. 1 depicts the EDSS and SNRS scores of the patients. The average EDSS and SNRS scores of patients receiving cladribine improved modestly during the first year of the study, whereas the scores of patients with placebo continued to deteriorate. The improvement in SNRS scores appeared to peak at 18 mo and be well maintained for the 24 mo of follow-up in the patients treated with 2.8 mg of cladribine per kg, even though they received no active drug after the first 4 mo of the study. After 24 mo, in unblinded observations, fairly rapid deterioration was documented. While the scores of the patients who received placebo in the first year of the study deteriorated during that year, the lower dose of cladribine they received (1.4 mg/kg) also seemed to be effective in stabilizing their disease, albeit for a shorter time period, with peak improvement at 8 mo after treatment initiation. Inspection of the curves thus suggests that the stabilization of disease produced by the lower dose of cladribine may be of shorter duration than that seen with the larger dose and that a rebound worsening of disease may occur between 24 and 30 mo after initiation of therapy with the higher dose. ANOVA based on the two-period crossover design with absolute changes in EDSS and SNRS as end points revealed no significant carryover effects between subjects or period effects within subjects, but highly significant treatment effects: the F-statistics for assessing treatment effects with subjects were F1,44 = Toxicity and adverse events. The average platelet counts remained normal throughout the study, but the platelet counts of seven patients receiving the larger cladribine dose in the first year of the study fell to <100,000/ul, and one of these, a patient who had taken carbamazepine (Tegretol) and who was ingesting large amounts of phenytoin (Dilantin), developed severe thrombocytopenia with platelet counts <10,00QOO,l.
The effect of cladribine on the blood counts of these patients has been reported in detail elsewhere (16) . In the second year of the study, when patients received only one-half of the dose of cladribine administered in the first year, platelet counts of <100,0001,ul were encountered in only one patient, the lowest count observed being 83,000/,ul. Changes in lymphocyte subsets are depicted in Fig. 3 . There was marked depletion of CD4 cells with both the high-and low-dose schedule.
Proc. Natl. Acad. Sci. USA 93 (1996) Six patients developed herpes zoster, one of them only after retreatment with cladribine under another protocol. All of these infections were segmental, mild, and responded rapidly to oral acyclovir. One patient developed fatal, fulminating, newly acquired hepatitis B immediately after her second dose of cladribine. As discussed elsewhere (7), it seems unlikely that the administration of cladribine played a role in this patient's illness. One patient developed a severe Salmonella infection with near-perforation of the bowel while receiving placebo during the first study year. She responded well to antibiotic therapy and continued the study.
DISCUSSION
Although numerous immunosuppressive and immunomodulatory drugs have been given to patients with MS, conventional immunosuppression has not demonstrated sufficient promise to be considered as a routine treatment for the chronic progressive form of MS (17) (18) (19) . Why then, might another immunosuppressive agent produce a greater effect? The suppression of CD4 cells and sparing of CD8 cells that was observed with cladribine administration is much greater than that observed with other immunosuppressive agents. Treatment of MS patients for a year with chlorambucil (18) and cyclophosphamide (20) each produced a relatively transient 2-fold decline in the CD4/CD8 ratio. In contrast, treatment with cladribine for only a few months produced an -4-fold decrease in this ratio, and the effect was sustained for many months after a 4-mo course of the drug.
Because (1996) given by the much more convenient subcutaneous route without causing local irritation and with pharmacokinetic (22) and therapeutic (23) 
